| 000 | a | ||
|---|---|---|---|
| 999 |
_c16275 _d16275 |
||
| 003 | OSt | ||
| 005 | 20220208145426.0 | ||
| 008 | 220208b xxu||||| |||| 00| 0 eng d | ||
| 040 |
_aAIKTC-KRRC _cAIKTC-KRRC |
||
| 100 |
_915948 _aSartaj Hussain |
||
| 245 | _aAntimicrobial agent’s utilization and cost pattern in medical intensive care unit of a tertiary care hospital | ||
| 250 | _aVol.13(2) | ||
| 260 |
_aM P _bInnovare Academic Sciences Pvt Ltd _c2021 |
||
| 300 | _a89-93p. | ||
| 520 | _aObjective: The objective of this study was to evaluate the utilization and cost pattern of AMAs (Antimicrobial Agents) in the Medical ICU of a tertiary care teaching hospital, and to determine the predictor of antimicrobial number per day. Methods: A prospective cross-sectional study was carried out and a total of 101 patients were studied. The drugs were classified into different groups according to the World Health Organization’s ATC (Anatomical Therapeutic Chemical) Classification System. Results: The mean [95% confidence interval (CI)] duration of ICU stay was 7.11 (5.70-8.52) days and the mortality rate in the ICU was 42.6%. The AMAs DDD (Defined Daily Dose) per 100 patient days and number of AMAs per prescription were 296.64 and 2.65, respectively. Piperacillin-tazobactam was the most commonly utilized AMAs followed by metronidazole, meropenem, fluconazole, and colistin. The mean number [95% CI] of AMAs, DDD, and cost (INR) per patient were 18.82 (14.05-23.59), 21.09 (15.36-26.81) and 25,827 (18,716-32,939) respectively. The AMAs constituted 88.53% of the total treatment cost. Meropenem was the most costly AMA (32.10% of the total AMAs cost) followed by imipenem-cilastatin (20.50%), colistin (14.65%), piperacillin-tazobactam (8.40%), and clindamycin (4.47%). The independent predictor for the antimicrobial number per day was acute physiology and chronic health evaluation II (APACHE-II) score at admission and nosocomial infections. Conclusion: The AMAs, DDD per 100 patient days, and number per prescription were higher. This leads to a higher cost of AMAs per patient and the AMAs cost out of the total cost as compared to previous studies. We suggest, there is a need to formulate and implement an antimicrobial restriction policy. | ||
| 650 | 0 |
_94639 _aPHARMACEUTICS |
|
| 700 |
_915949 _aYadav, Suraj Singh |
||
| 773 | 0 |
_tInternational journal of pharmacy and pharmaceutical science _x2656-0097 _dBhopal Innovare Academic Sciences Pvt Ltd |
|
| 856 |
_uhttps://innovareacademics.in/journals/index.php/ijpps/article/view/41338 _yClick here |
||
| 942 |
_2ddc _cAR |
||